➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
Moodys
Johnson and Johnson
Medtronic
AstraZeneca

Last Updated: September 23, 2021

DrugPatentWatch Database Preview

Aflibercept - Biologic Drug Details


Email this page to a colleague

« Back to Dashboard

Recent Clinical Trials for aflibercept

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Berner Augenklinik am LindenhofspitalN/A
medignition AGN/A
Clover Biopharmaceuticals AUS Pty LtdPhase 1

See all aflibercept clinical trials

Recent Litigation for aflibercept

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Novartis Pharma AG v. Regeneron Pharmaceuticals, Inc.2020-06-19
Regeneron Pharmaceuticals, Inc. v. Genentech, Inc.2011-02-17

See all aflibercept litigation

PTAB Litigation
PetitionerDate
Regeneron Pharmaceuticals, Inc.2021-04-16
Regeneron Pharmaceuticals, Inc.2020-07-16

See all aflibercept litigation

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for aflibercept Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for aflibercept Derived from Company Disclosures

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Regeneron Pharmaceuticals EYLEA aflibercept INJECTABLE; INJECTION 125387 001 2011-11-18 ⤷  Try it Free Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) 2019-06-08 RX company
Regeneron Pharmaceuticals EYLEA aflibercept INJECTABLE; INJECTION 125387 001 2011-11-18 ⤷  Try it Free Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) 2039-02-26 RX company
Regeneron Pharmaceuticals EYLEA aflibercept INJECTABLE; INJECTION 125387 001 2011-11-18 ⤷  Try it Free Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) 2039-02-26 RX company
Regeneron Pharmaceuticals EYLEA aflibercept INJECTABLE; INJECTION 125387 001 2011-11-18 ⤷  Try it Free Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) 2039-03-29 RX company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

3) Low Certainty: US Patents for aflibercept Derived from Patent Text Search

These patents were identified by searching patent claims

Supplementary Protection Certificates for aflibercept

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2013 00020 Denmark ⤷  Try it Free
90020-4 Sweden ⤷  Try it Free PRODUCT NAME: AFLIBERCEPT; REG. NO/DATE: EU/1/12/797/001 20121122
2013009,C1183353 Lithuania ⤷  Try it Free PRODUCT NAME: AFLIBERCEPTUM; REGISTRATION NO/DATE: EU/1/12/797/001, 2012 11 22 EU/1/12/797/002, 2012 11 22 EU/1/12/814 20130201
13C/029 Belgium ⤷  Try it Free PRODUCT NAME: AFLIBERCEPT; AUTHORISATION NUMBER AND DATE: EU/1/12/197/001 20121126
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
McKesson
Colorcon
Dow
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.